十年的生物技术失误。 - Suppr

Suppr

超能文献

Ten years of biotech gaffes.

作者信息

Hodgson John

机构信息

Critical I Ltd., The Colin Sanders Innovation Centre, Mewburn Road, Banbury, OX16 9PA, UK.

出版信息

Nat Biotechnol. 2006 Mar;24(3):270-3. doi: 10.1038/nbt0306-270.

DOI:10.1038/nbt0306-270

PMID:16525384

Abstract

摘要

相似文献

Ten years of biotech gaffes.

Nat Biotechnol. 2006 Mar;24(3):270-3. doi: 10.1038/nbt0306-270.

Errors in patent application sequence listings.

Nat Biotechnol. 2003 Oct;21(10):1239-40. doi: 10.1038/nbt1003-1239.

Publish and perish: what constitutes a bar under the patent laws.

Nat Biotechnol. 2004 Nov;22(11):1449-51. doi: 10.1038/nbt1104-1449.

The coming US patent opposition.

Nat Biotechnol. 2005 Feb;23(2):245-7. doi: 10.1038/nbt0205-245.

The level of disclosure necessary for patent protection of genetic innovations.

Nat Biotechnol. 2004 Oct;22(10):1307-8. doi: 10.1038/nbt1004-1307.

Inter partes reexamination: a potentially useful approach to challenging invalid biotechnology patents.

Nat Biotechnol. 2003 Jul;21(7):823-5. doi: 10.1038/nbt0703-823.

Brussels takes EU states to court over biopatent law.

Nat Biotechnol. 2003 Sep;21(9):960. doi: 10.1038/nbt0903-960.

New guidance on the patentability of embryonic stem cell patents in Europe.

Nat Biotechnol. 2009 Apr;27(4):338-9. doi: 10.1038/nbt0409-338.

Patents: patenting of stem cell related inventions in Europe.

Biotechnol J. 2006 Apr;1(4):384-7. doi: 10.1002/biot.200600021.

The prevalence of patent interferences in gene technology.

Nat Biotechnol. 2004 Feb;22(2):153-4. doi: 10.1038/nbt0204-153.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Ten years of biotech gaffes.

Nat Biotechnol. 2006 Mar;24(3):270-3. doi: 10.1038/nbt0306-270.

Errors in patent application sequence listings.

Nat Biotechnol. 2003 Oct;21(10):1239-40. doi: 10.1038/nbt1003-1239.

Publish and perish: what constitutes a bar under the patent laws.

Nat Biotechnol. 2004 Nov;22(11):1449-51. doi: 10.1038/nbt1104-1449.

The coming US patent opposition.

Nat Biotechnol. 2005 Feb;23(2):245-7. doi: 10.1038/nbt0205-245.

The level of disclosure necessary for patent protection of genetic innovations.

Nat Biotechnol. 2004 Oct;22(10):1307-8. doi: 10.1038/nbt1004-1307.

Inter partes reexamination: a potentially useful approach to challenging invalid biotechnology patents.

Nat Biotechnol. 2003 Jul;21(7):823-5. doi: 10.1038/nbt0703-823.

Brussels takes EU states to court over biopatent law.

Nat Biotechnol. 2003 Sep;21(9):960. doi: 10.1038/nbt0903-960.

New guidance on the patentability of embryonic stem cell patents in Europe.

Nat Biotechnol. 2009 Apr;27(4):338-9. doi: 10.1038/nbt0409-338.

Patents: patenting of stem cell related inventions in Europe.

Biotechnol J. 2006 Apr;1(4):384-7. doi: 10.1002/biot.200600021.

The prevalence of patent interferences in gene technology.

Nat Biotechnol. 2004 Feb;22(2):153-4. doi: 10.1038/nbt0204-153.